Apremilast in patients with moderate to severe psoriasis: Results of a phase 3, randomized, controlled trial (ESTEEM 2)

被引：0
|
作者：
Mrowietz, U. [1 ]
Paul, C. [2 ]
Gooderham, M. [3 ]
Cather, J. [4 ]
Poulin, Y. [5 ]
Girolomoni, G. [6 ]
Ferrandiz, C. [7 ]
Gottlieb, A. [8 ]
Hu, C. C. [9 ]
Day, R. [9 ]
Crowley, J. [10 ]
机构：
[1] Univ Hosp Schleswig Holstein, Kiel, Germany
[2] Toulouse Univ, Hop Larrey, Toulouse, France
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Modern Res Associates, Dallas, TX USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] Univ Verona, I-37100 Verona, Italy
[7] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
[8] Tufts Med Ctr, Boston, MA USA
[9] Celgene Corp, Warren, MI USA
[10] Bakersfield Dermatol, Bakersfield, CA USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV08/02
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1)
    Papp, Kim
    Griffiths, Christopher
    Leonardi, Craig
    Reich, Kristian
    Kircik, Leon
    Day, Robert
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB164 - AB164
  • [2] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
  • [3] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1)
    Reich, K.
    Papp, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C.
    Stevens, R.
    Day, R. M.
    Griffiths, C. E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 22 - 23
  • [4] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig L.
    Kircik, Leon
    Chimenti, Sergio
    Langley, Richard G. B.
    Hu, ChiaChi
    Stevens, Randall M.
    Day, Robert M.
    Gordon, Kenneth B.
    Korman, Neil J.
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : 37 - 49
  • [5] Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)
    Papp, Kim A.
    Reich, Kristian
    Sobell, Jeffrey M.
    Menter, Alan
    Lacour, Jean-Philippe
    Chimenti, Sergio
    Hu, ChiaChi
    Day, Robert M.
    Shah, Kamal
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [6] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: ESTEEM 1 randomized treatment withdrawal phase results
    Foley, P.
    Papp, K.
    Reich, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C. C.
    Stevens, R. M.
    Day, R. M.
    Griffiths, C. E. M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 35 - 35
  • [7] Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
    Imafuku, Shinichi
    Nemoto, Osamu
    Okubo, Yukari
    Komine, Mayumi
    Schafer, Peter
    Petric, Rosemary
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (01): : 80 - 84
  • [8] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 52-week results of the ESTEEM 2 Trial
    Paul, C.
    Gooderham, M.
    Cather, J.
    Poulin, Y.
    Girolomoni, G.
    Ferrandiz, C.
    Gottlieb, A. B.
    Mrowietz, U.
    Hu, Cc.
    Day, R. M.
    Richter, S.
    Crowley, J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 63 - 63
  • [9] Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)
    Reich, Kristian
    Griffiths, Christopher
    Leonardi, Craig
    Papp, Kim
    Kircik, Leon
    Day, Robert
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
  • [10] Efficacy and safety of apremilast with or without topical or phototherapy: Subanalysis of the population with < PASI-75 in the ESTEEM 1 phase 3, randomized, controlled trial in patients with moderate to severe plaque psoriasis
    Reich, Kristian
    Kircik, Leon
    Paris, Maria
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB246 - AB246
12345